Fig. 1

MiR-24-2-5p expression levels in the serum from BC patients, human BC cell lines, and small extracellular vesicles derived from BC cell lines. A Receiver operating characteristic (ROC) curves analysis for miR-24-2-5p to predict bone relapse, either alone (left panel) or in combination with patients’ tumour grade (TGRADE) (right panel). B Violin plot showing miR-24-3p, miR-24-1-5p and miR-24-2-5p expression levels in the serum from early-stage BC patients who did not relapse (NOMET, n = 16) versus BC patients who relapsed in bone (BONEMET, n = 16). C Comparison of the expression levels of miR-24-3p, miR-24-1-5p and miR-24-2-5p between NOMET and BONEMET groups. Only miR-24-2-5p expression levels showed a significant fold change (Log₂FC≤-0.5, p = 0.02) between both groups. D Expression levels of miR-24-2-5p in different subtypes of human BC cell lines (luminal A, luminal B, HER+, TNBC). E Expression levels of miR-24-2-5p in the CCLE BC cell collection database (45 tumour cell lines sub-grouped into 4 BC subtypes). F Expression levels of miR-24-2-5p in small extracellular vesicles (sEVs) secreted from NW1 cells compared to the cells of origin. G Expression levels of miR-24-2-5p in sEVs secreted from SK-BR-3 cells compared to the cells of origin. Data are the mean ± SEM of three independent experiments, * p ≤ 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001